SeekingAlphaAugust 28, 2026 at 12:07 PM NY7 days ago

BioNTech: Reiterating Strong Buy Based On COMIRNATY Variant Expansion And More

BioNTech SE maintains a Strong Buy rating, driven by robust late-stage oncology pipeline momentum and strategic partnerships. Click for more on BNTX.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — SeekingAlpha

Companies in This Story